Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533308 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL2722875 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18085405 | 0.92 | CPB1 (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL28522803 | 0.89 | LMNA (0.54) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL28522801 | 0.89 | LMNA (0.54) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL2724463 | 0.88 | SLC1A3 (0.58) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL2723527 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18086889 | 0.87 | CTSK (0.55) | LMNASMN1; SMN2HTTCTSKCTSS | |
| SCHEMBL6946489 | 0.86 | HTT (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL6943807 | 0.86 | HTT (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926261-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160271082-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271082-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | LMNA 3801/4885SMN1; SMN2 4878/4885SLC1A3 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.